CONMED Corp. Q1 2002 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2002. CONMED Corporation is a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, powered surgical instruments, electrosurgery systems, endoscopy products, and patient care devices. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $113,205 | $105,909 |
| Gross Margin | 52.2% | 53.1% |
| Operating Income | $20,809 | $17,710 |
| Net Income | $9,076 | $6,003 |
| Diluted EPS | $0.35 | $0.26 |
| Operating Cash Flow | $12,351 | $11,116 |
| Total Debt (Current + Long-term) | $325,991 | $335,929 |
| Cash and Equivalents | $2,634 | $4,104 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.9% year-over-year. Organic growth was approximately 1.0%, with the remainder driven by the second Imagyn acquisition ($6.5 million in new product revenue).
- Profitability: Net income rose 51% to $9.1 million. This increase was significantly aided by the adoption of SFAS 142, which eliminated goodwill amortization, adding approximately $1.4 million to net income.
- Product Mix: Orthopedic sales declined 1.6% due to a 7.2% drop in powered surgical instruments (impacted by a product transition to the PowerPro line). Conversely, electrosurgery sales grew 12.0% and endoscopy sales surged due to the Imagyn acquisition.
- Interest Expense: Decreased 20% to $6.6 million due to lower total borrowings and reduced weighted average interest rates (4.20% on term loans vs. 7.94% in 2001).
Outlook, Risks, and Unusual Items
- Debt Refinancing: The $100 million revolving credit facility expires December 31, 2002. Management is negotiating an extension or renegotiation. They anticipate interest costs may rise 75 to 100 basis points, potentially increasing annual interest expense by $1.3 million to $1.7 million.
- Capital Raising: On April 30, 2002, the company filed a registration statement to sell up to 3,450,000 shares of common stock to repay outstanding debt. The statement was not yet effective at the time of filing.
- Accounting Change: Adoption of SFAS 142 on January 1, 2002, discontinued amortization of goodwill and certain intangibles. No impairment losses were recognized in the first quarter.
- Liquidity: Net working capital improved to $47.4 million. The company maintains a $40 million accounts receivable sales facility to optimize working capital.
Investor Verification Checklist
- Verify the status and terms of the revolving credit facility renegotiation, specifically the expected interest rate increase.
- Monitor the effectiveness of the April 30, 2002, registration statement for the sale of common stock.
- Assess the long-term impact of the transition to the new PowerPro battery-powered product line on orthopedic sales volumes.
- Review the sustainability of the 12% growth in electrosurgery sales and the integration of the Imagyn endoscopy product lines.
- Confirm that the company continues to meet the statistical ratios required to maintain the $40 million accounts receivable sales facility.